Dual Antiplatelet Therapy with Aspirin and Clopidogrel for 21 Days
Patients with minor ischemic stroke (NIHSS score <5) or high-risk TIA (ABCD2 score >4) without atrial fibrillation should receive dual antiplatelet therapy with aspirin and clopidogrel for 21-30 days, followed by single antiplatelet therapy. The answer is C.
Treatment Protocol
Loading doses should be administered immediately after brain imaging excludes intracranial hemorrhage 1, 2:
- Clopidogrel: 300-600 mg loading dose (300 mg based on CHANCE trial, 600 mg based on POINT trial)
- Aspirin: 160-325 mg loading dose
Maintenance therapy for 21-30 days 1, 2:
- Clopidogrel 75 mg daily
- Aspirin 81-100 mg daily
After 21-30 days: Switch to single antiplatelet therapy (aspirin 81 mg daily OR clopidogrel 75 mg daily) indefinitely 1, 2.
Timing Considerations
Dual antiplatelet therapy must be initiated within 24 hours of symptom onset, ideally within 12 hours 1, 2. The treatment should begin prior to discharge from the emergency department 1.
Evidence Base
The recommendation is based on Level A evidence from two major trials 1:
- CHANCE trial: Demonstrated that dual antiplatelet therapy for 21 days significantly reduced ischemic stroke risk in this population
- POINT trial: Showed 4.6% vs 6.3% stroke risk (HR 0.72, p=0.01) with dual therapy, though major hemorrhage increased (0.9% vs 0.4%)
The critical limitation to 21-30 days is based on the bleeding risk 1. The POINT trial estimated that for every 1000 patients treated for 90 days, 15 ischemic strokes would be prevented but 5 major hemorrhages would result. This unfavorable risk-benefit ratio beyond 21-30 days is why guidelines specifically limit dual therapy duration 1.
Why Other Options Are Incorrect
Aspirin alone (Option A) is insufficient for this high-risk population and represents outdated management 1, 2.
Clopidogrel alone (Option B) is also inadequate for the acute high-risk period, though it becomes appropriate after completing the 21-30 day dual therapy course 1, 2.
Anticoagulant therapy (Option D) is not indicated for non-cardioembolic stroke and increases bleeding risk without benefit 3.
Thrombolysis (Option E) is not appropriate for minor stroke with NIHSS <5, as recent evidence from the ARAMIS trial 4 demonstrated that dual antiplatelet therapy is noninferior to alteplase in minor nondisabling stroke, with lower bleeding risk.
Important Clinical Caveats
For patients with high-grade carotid stenosis requiring urgent endarterectomy or stenting, aspirin monotherapy may be more appropriate than dual therapy to reduce perioperative bleeding risk—this decision should be made in consultation with the surgeon or interventionalist 1.
GI protection should be considered in patients at higher risk of gastrointestinal bleeding during the dual antiplatelet therapy period 1.
Patients must be counseled that dual therapy is time-limited to 21-30 days only, after which they should resume monotherapy indefinitely 1.
The 2023 World Stroke Organization guidelines 2 and 2018 Canadian Stroke Best Practice recommendations 1 are in complete agreement on this approach, representing the current international standard of care for this specific patient population.